GL1X · GenesisL1 explorer

MolNFT v1 · #164188 · protein

Structure of protein kinase CK2 catalytic subunit in complex with the CK2BETA-competitive bisubstrate inhibitor ARC1502

6SPX · Casein kinase II subunit alpha: “Structure of protein kinase CK2 catalytic subunit in complex with the CK2BETA-competitive bisubstrate…”. X-ray diffraction, 1 ligand (9AB), 2 pockets (best druggability 0.70). MolNFT v1 #164188 on…

PDB
6SPX
Type
protein
Length
336 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Casein kinase II subunit alpha; ARC1502
EC
2.7.11.1
UniProt
P68400
Ligands
9AB
Pockets
2 · best druggability 0.70

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACasein kinase II subunit alpha (EC 2.7.11.1)protein32939% helix, 15% strandP68400
BARC1502protein70% helix, 0% strand—

Ligands and binding sites

  • 9AB · 8-[4,5,6,7-tetrakis(bromanyl)benzimidazol-1-yl]octanoic acid · ligand · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13940.700.82459AB
2590.320.7614empty

Interfaces

1 interface between chains.

  • A–B · 690 Ų buried · 27 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 covalent, 1 d-amino (covalent ligand, D-amino acid).

Compared structures

  • 6SPX · Structure of protein kinase CK2 catalytic subunit in complex with the CK2beta-competitive… · the same entry in another collection · chain A against A, TM-score 1.00
  • P68400 · AlphaFold monomer V2.0 prediction for casein kinase II subunit alpha (P68400) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.